title: Use of midodrine (Gutron) to treat permanent hypotension in a chronic hemodialysis patient.
abstract: Chronic hypotension, infrequent though possible in chronic renal failure patients on hemodialysis, has harmful consequences on their physical state and hence general well-being. These patients often experience acute intradialytic manifestations while non-pharmacologic interventions as pharmacologic agents are sometimes insufficient to improve symptoms. Well tolerated, midodrine appears to be a suitable and effective agent as it raises blood pressure significantly via its effect on peripheral alpha-adrenergic receptors. The authors describe their use of midodrine in a dialysis patient for the longest period of time reported up to now, documented by a pharmacokinetic study, confirming long-term both clinical efficacy and safety of the drug.
authors.affiliation: Department of Nephrology-Hemodialysis, Troyes General  Hospital, France.
authors.forename: R
authors.initials: R
authors.lastname: Montagnac
authors.forename: P
authors.initials: P
authors.lastname: Clavel
authors.forename: B
authors.initials: B
authors.lastname: Delhotal-Landes
authors.forename: B
authors.initials: B
authors.lastname: Flouvat
authors.forename: S
authors.initials: S
authors.lastname: Poulain
authors.forename: F
authors.initials: F
authors.lastname: Schllinger
mesh_terms: D001794:Blood Pressure / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007022:Hypotension / Q000188:drug therapy* / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000628:therapy; D008297:Male; D008875:Middle Aged; D008879:Midodrine / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006435:Renal Dialysis / Q000009:adverse effects*; D014662:Vasoconstrictor Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*
chemical_list: D014662:Vasoconstrictor Agents; D008879:Midodrine